Navigation Links
Pharmasset Reports Fiscal Year End 2011 Financial Results
Date:11/14/2011

PRINCETON, N.J., Nov. 14, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal year ended September 30, 2011. At fiscal year end Pharmasset held $166.5 million in cash and cash equivalents and used $21.7 million of our cash and cash equivalents during the fourth quarter of fiscal 2011.

Pipeline Update and 2011 HighlightsPSI-7977The recently-announced registrational program for PSI-7977, the once-a-day nucleotide analog for hepatitis C virus (HCV) infection, is the first to pursue an interferon-free, all-oral regimen, and the first to include patients with all HCV genotypes (GT). The three core studies will evaluate the all-oral two-drug combination of PSI-7977 and ribavirin (RBV) administered for 12 weeks.

The first trial, FISSION, is a pivotal study of PSI-7977 with RBV for 12 weeks in approximately 500 patients with HCV GT2 or GT3. FISSION is designed to demonstrate the superiority of PSI-7977/RBV over the current standard-of-care for HCV GT2/3, pegylated interferon (Peg-IFN) and ribavirin for 24 weeks. The second Phase 3 trial, POSITRON, is planned to begin in early 2012. POSITRON will enroll approximately 225 patients with HCV GT2 or GT3 who cannot take interferon, thus supporting a placebo comparator arm for this trial. During the first quarter of 2012, data from ongoing open-label assessments of PSI-7977/RBV in subjects with HCV GT1 in ELECTRON and QUANTUM will be reviewed and incorporated into the final design for the third registrational trial, NEUTRINO. This trial will also investigate a 12-week regimen of PSI-7977/RBV versus a placebo comparator, and will enroll approximately 280 patients with HCV regardless of viral genotype, inclu
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
2. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
5. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
8. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
9. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
10. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
11. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 NextCODE Health, which enables clinicians and ... real time, today announced the launch of its new genomic ... at the American Society of Human Genetics (ASHG) annual meeting ... sign up and apply for free beta access, visit ... benefits can be viewed here . The ...
(Date:10/19/2014)... report "Chocolate, Cocoa Beans, Lecithin, Sugar and Vanilla Market ... (2011 - 2016)," analyzes the chocolate market by ... market drivers, restraints, and opportunities for the chocolate market ... chocolate market is expected to grow from $83.2 billion ... CAGR of 2.7% from 2011 to 2016. , Get ...
(Date:10/18/2014)... The “Human Insulin Market- by Product ... Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], ... Others) - Forecast to 2018” provides a detailed ... current market trends, and strategies impacting the global ... forecasts of the revenue and share analysis. , ...
(Date:10/18/2014)... Asia-Pacific hardware encryption display market report defines and segments ... of revenue. This market was valued $5,154.0 million in ... 2018, at a CAGR of 58.4% from 2013 to ... hardware encryption market report, to get an idea of ... of the segmentation of the market, and is supported ...
Breaking Biology Technology:The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3
... WEST CONSHOHOCKEN, Pa., Nov. 12 GEL Interactive,Technologies, ... Kent,Senior Product Director, will be a featured speaker ... Annual Forum on Defining Appropriate,and Effective Interactions with ... 5th Annual Forum provides a platform for attendees ...
... MELBOURNE, Australia, Nov. 12 Phosphagenics,Limited ("Phosphagenics") (ASX: ... initiated a phase 1 human clinical trial ... the targeted delivery of a leading non ... compare the,bioavailability and penetration of the topically ...
... EMERYVILLE, Calif., Nov. 12 Bionovo, Inc.,(Nasdaq: BNVI ... to the,company,s Scientific Advisory Board. Dr. Weiss is a ... a leading researcher,at the Cardiovascular Research Institute and the ... (UCSF)., "We are very excited to have Ethan ...
Cached Biology Technology:Cadient Group's GEL Interactive Technologies to Present and Exhibit at CBI's 5th Annual Forum 2Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans 2Ethan Weiss, M.D., Joins Bionovo's Scientific Advisory Board 2Ethan Weiss, M.D., Joins Bionovo's Scientific Advisory Board 3
(Date:10/16/2014)... synthesis of recent research findings to inform their management ... states. , The Ecology and Management of Moist ... of the Relevant Biophysical Science and Implications for Future ... U.S. Forest Service,s Pacific Northwest Research Station, is a ... synthesis of the large body of scientific information on ...
(Date:10/16/2014)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market announces ... the Smart Wallet, at the 13 th annual ... global conference on the intersection of technology and the ... , founder and publisher of the Strategic News Service™, ...
(Date:10/15/2014)... is spreading rapidly and to an unexpected extent. The ... past and the virus shows a new disease dynamic ... For this reason, the German National Academy of Sciences ... Engineering, and the Union of the German Academies of ... Ebola epidemic today. , In the statement the academies ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... a share of grants totalling over 1m to target ... Dr. Declan Bates, a senior lecturer in the Department ... of 1,068,000 in the form of just two research ... Council (EPSRC) and the other from the Biotechnology and ...
... molecular mechanisms by which plants protect themselves from oxidation ... a team of researchers has discovered a molecular dimmer ... moving through the system of light harvesting proteins. This ... artificial photosynthesis systems that could provide the world with ...
... Fla. Two University of Miami (UM) students have ... Foundation (NSF) for their doctoral work on coral reefs. ... years of support for their work in the laboratory ... Division of Marine Biology and Fisheries at UMs Rosenstiel ...
Cached Biology News:Engineer to spearhead research into cell metabolism and medical injuries 2Berkeley researchers identify photosynthetic dimmer switch 2Berkeley researchers identify photosynthetic dimmer switch 3Berkeley researchers identify photosynthetic dimmer switch 4Everything's coming up corals 2Everything's coming up corals 3
Cell Culture Flask, 175 cm, tissue-culture treated polystyrene, barcoded...
... incubation trays are disposable trays ... antigens that have been blotted ... has eight 10.5 cm x ... strips cut from blotted membrane ...
... in permanent mounting media. It is ... immunohistochemical organic insoluble substrates such as ... and any other organic solvent compatible ... can be used for histology and ...
... The Gene Inspector can perform many sophisticated DNA ... is much more than just another sequence analysis ... entire suite of analyses to be performed each ... design custom style sheets which specify exactly how ...
Biology Products: